These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 18335586)
41. The perils and possibilities of the private health sector. Horton R; Clark S Lancet; 2016 Aug; 388(10044):540-1. PubMed ID: 27358254 [No Abstract] [Full Text] [Related]
42. Reform of health care financing systems. Graham S J S C Med Assoc; 2008 Apr; 104(4):106; author reply 106-7. PubMed ID: 18557327 [No Abstract] [Full Text] [Related]
43. Private sector contributions to pharmaceutical science: thirty-five summary case histories. Zycher B; DiMasi JA; Milne CP Am J Ther; 2010; 17(1):101-20. PubMed ID: 20027102 [TBL] [Abstract][Full Text] [Related]
44. Costly health care: a lesson from New Zealand. Bassett M Health Care Anal; 1993 Nov; 1(2):189-96. PubMed ID: 10135600 [No Abstract] [Full Text] [Related]
45. 2 billion euro IMI launched with European pharma. Hodgson J Nat Biotechnol; 2008 Jul; 26(7):717-8. PubMed ID: 18612274 [No Abstract] [Full Text] [Related]
46. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nwaka S; Ridley RG Nat Rev Drug Discov; 2003 Nov; 2(11):919-28. PubMed ID: 14668812 [No Abstract] [Full Text] [Related]
47. The private sector role in HIV/AIDS in the context of an expanded global response: expenditure trends in five sub-Saharan African countries. Sulzbach S; De S; Wang W Health Policy Plan; 2011 Jul; 26 Suppl 1():i72-84. PubMed ID: 21729920 [TBL] [Abstract][Full Text] [Related]
48. Improving vaccine supply and development: who needs what? Pauly MV Health Aff (Millwood); 2005; 24(3):680-9. PubMed ID: 15886159 [TBL] [Abstract][Full Text] [Related]
50. The innovative medicines initiative: a European response to the innovation challenge. Goldman M Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619 [TBL] [Abstract][Full Text] [Related]
52. Funding in the firing line. Do governments have a duty to fund the full spectrum of scientific research, or can the private sector be relied upon to pick up the slack? Wolinsky H EMBO Rep; 2011 Jul; 12(8):772-4. PubMed ID: 21799528 [No Abstract] [Full Text] [Related]
53. Private health sector in India: let's not confuse the issues. Rajan TD BMJ; 2005 Dec; 331(7528):1339. PubMed ID: 16322036 [No Abstract] [Full Text] [Related]
57. Increase in public spending on health slowed in 2010, as private health spending rose. Limb M BMJ; 2012 May; 344():e3246. PubMed ID: 22569870 [No Abstract] [Full Text] [Related]
58. Is there transparency in the pricing of medicines in the South African private sector? Bangalee V; Suleman F S Afr Med J; 2018 Feb; 108(2):82-83. PubMed ID: 29429435 [TBL] [Abstract][Full Text] [Related]
59. [Commercialization of results of intellectual activities in pharmaceutical industry]. Posylkina OV; Timaniuk VN; Gladukh EV Lik Sprava; 2002; (8):16-9. PubMed ID: 12669531 [TBL] [Abstract][Full Text] [Related]